Tell your health care provider about all the medicines you take.
Your provider will tell you if you need to temporarily stop taking any medicines before you have this test. This includes blood thinners such as aspirin, heparin, streptokinase, and urokinase, which make it hard for the blood to clot.
Do not stop or change your medicines without talking to your doctor first.
How the Test will Feel
When the needle is inserted to draw blood, some people feel moderate pain. Others feel only a prick or stinging. Afterward, there may be some throbbing or slight bruising. This soon goes away.
Why the Test is Performed
This test is done to see if your clot-dissolving (fibrinolytic) system is working properly. Your doctor may order this test if you have signs of disseminated intravascular coagulation (DIC) or another clot-dissolving disorder.
The result is normally less than 10 mcg/mL.
Note: Normal value ranges may vary slightly among different laboratories. Some labs use different measurements or may test different specimens. Talk to your doctor about the meaning of your specific test results.
What Abnormal Results Mean
Increased FDPs may be a sign of primary or secondary fibrinolysis (clot-dissolving activity) due to a variety of causes, including:
There is very little risk involved with having your blood taken. Veins and arteries vary in size, so it may be harder to take a blood sample from one person than another.
Other slight risks from having blood drawn may include:
Fainting or feeling lightheaded
Hematoma (blood accumulating under the skin)
Infection (a slight risk any time the skin is broken)
Brummel-Ziedins K. Mann KG. Molecular basis of blood coagulation. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013:chap 128.
Levi M. Disseminated intravascular coagulation. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013:chap 128.
Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.